Linagliptin Parent Nucleus Intermediate CAS 853029-57-9 Purity ≥99.0% Factory

Short Description:

Name: Linagliptin Parent Nucleus Intermediate

CAS: 853029-57-9

Purity: ≥99.0%

Appearance: White to Light Yellow Powder

Intermediate for Linagliptin (CAS: 668270-12-0) for the treatment type II diabetes mellitus

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Manufacturer Supply Linagliptin and Related Intermediates:
Linagliptin CAS 668270-12-0
Linagliptin Parent Nucleus Intermediate CAS 853029-57-9
8-Bromo-3-Methylxanthine CAS 93703-24-3
8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine CAS 666816-98-4
2-(Chloromethyl)-4-Methylquinazoline CAS 109113-72-6
(R)-3-(Boc-Amino)piperidine CAS 309956-78-3
(R)-(-)-3-Aminopiperidine Dihydrochloride CAS 334618-23-4
1-Bromo-2-Butyne CAS 3355-28-0

Chemical Properties:

Chemical Name	8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
Synonyms	Linagliptin Parent Nucleus; Linagliptin Intermediate F
CAS Number	853029-57-9
CAT Number	RF-PI502
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C20H17BrN6O2
Molecular Weight	453.29
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Light Yellow Powder
Identification	IR/HPLC
Purity	≥99.0%
Water (K.F)	≤1.0%
Residue on Ignition	≤0.50%
Total Impurities	≤1.0%
Test Standard	Enterprise Standard
Usage	Intermediate for Linagliptin (CAS: 668270-12-0)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

FAQ:

Application:

8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (CAS: 853029-57-9) is the parent nucleus of Linagliptin (CAS: 668270-12-0). Linagliptin (trade names Tradjenta and Trajetna) is an inhibitor of dipeptidyl peptidase-4 (DPP-4) that was approved by the U.S. FDA in May 2011 for the treatment of Type 2 diabetes along with diet and exercise. Linagliptin (BI-1356) has been described as a potent highly selective, slow-off rate and long acting inhibitor of DPP-4. Linagliptin arose from optimization efforts of xanthine-based DPP-4 inhibitors with the initial lead identified from an HTS campaign.